Antiangiogenic Activities of Anti-Bfgf Monoclonal Antibodies
WANG Panpan,WANG Hong,LI Dan,XIANG Junjian,DENG Ning
DOI: https://doi.org/10.13431/j.cnki.immunol.j.20110071
2011-01-01
Abstract:The aim is to research the antiangiogenic activities of anti-bFGF monoclonal antibody in human umbilical vein endothelial cell(HUVECs) and chicken embryo allantois membrane(CAM).Three strains of anti-bFGF monoclonal antibodies,MabF7,MabF10,MabF12,were prepared and purified.We examined the HUVEC proliferation,migration,and tube formation by Cell Counting Kit(CCK-8),Transwell Cab,and ECM gel,respectively.The results showed that MabF7,MabF10,MabF12 could neutralize bFGF and suppress the proliferation,migration and tube formation of the HUVEC cell in vitro.The migration ratio of medium control,antibody control,and anti-bFGF antibodies(MabF7,MabF10,MabF12) were respectively 100%,106.25%±7.89%,69.50%±6.86%,74.00%±4.16%,67.75%±3.30%;the tube formation ratio were respectively 100%,105.93%±3.85%,56.53%±4.35%,29.23%±6.45%,12.77%±2.67%.Also,the anti-bFGF antibodies can inhibit the angiogenesis in CAM.The number of the radiated micrangium in bFGF control,bFGF+MabF7 group,bFGF+MabF10 group,bFGF+MabF12 were respectively 15±0.82,7.5±1.29,13.5±3.10,8.5±0.58.The results concluded that the anti-bFGF monoclonal antibody can inhibit the proliferation,migration,and tube formation of blood endothelium cells in vitro,and the anti-bFGF antibody can also inhibit the angiognensis in CAM,which will promote the research of antitumor medicine.